New York, US – Jan 23, 2019 – As a leader in recombinant antibody discovery and manufacturing, Creative Biolabs has dedicated itself to providing a variety of high-quality Fab fragment antibodies for its customers all over the world. Moreover, the company will continue to optimize the list to better fulfill the market demands.
Structurally, Fab fragments comprise two sets of variable and constant components, which create two polypeptide chains. Together they form a stable structure. The Fab fragment antibodies bind directly to the paratope of the target antibody, indicating that they vie with the drug for the binding site and thus have an inhibitory feature. Fab fragment antibodies have multiple applications. For instance, they can be used to detect not bound or free drugs in the serum. Sometimes, they help to prevent the adverse effects caused by the unspecific binding of the Fc of the antibody, which is missing in the Fab fragment. In particular cases, the Fab fragments can be converted into the recombinant immunoglobulin G (IgG) form, if necessary, for example, when the immunoglobulin is the preferable option for the disease treatment. The applications are primarily attributed to the unique chemical nature and physical structure of Fab antibodies.
“As one of recombinant antibodies, the fragment antibody functions as the functional component of the whole molecule. Compared with the intact antibodies, fragment antibodies boast several advantages. First, they come with lowered nonspecific binding from Fc interactions. Second, they are considered more efficient in penetrating tissue sections, leading to improved staining in immunohistochemistry. Third, they have a potential to develop higher sensitivity in antigen detection in solid phase applications due to reduced steric hindrance from large protein epitopes. Fourth, they play a big role in eliminating Fc-associated effector functions (e.g. complement fixation) in antigen-antibody binding studies. Fifth, when studying the structural basis for immune recognition by means of X-ray crystallography, we agree that antibody fragments have a simpler system than that of intact antibodies. Sixth, in in vivo experiments, fragment antibodies come with lower immunogenicity than intact antibodies. It’s exactly these advantages that impulse us to make great efforts to develop a host of superior Fab antibodies,” a scientist at Creative Biolabs replied in the interview.
Admittedly, Fab fragment antibodies do have a wide range of strengths, which are of great significance to the medical research. That’s why the development of Fab fragment antibodies has become ever more important. Therefore, it can be predicted that there will be an increasing number of high-quality Fab antibodies produced to satisfy the future market demands.
About Creative Biolabs
Creative Biolabs has optimal hybridoma development and phage display platforms, which enable the production of the most comprehensive list of recombinant antibody products and extensive service portfolio at the most competitive price. The company provides products ranging from antibody/peptide libraries, biosimilar cell lines, chimeric antigen receptor products, antibody-drug conjugates to engineered antibodies such as therapeutic antibodies, single-domain antibodies, bispecific antibodies and intrabodies.
Media ContactCompany Name: Creative BiolabsContact Person: Candy SwiftEmail: Send EmailPhone: 1-631-619-7922Address:45-1 Ramsey Road City: ShirleyState: New YorkCountry: United StatesWebsite: www.creativebiolabs.net
